Take the Chance
How to Become a UICC President
PATINA: Major FDA–EMA Divide Over Palbociclib in HER2+ Breast Cancer
Follicular Lymphoma: EHA 2026 Guidelines Move Chemotherapy-Free Combinations to First Relapse
The Promise on Hold: Takeda and Pfizer still to respond to help a Nigerian child with Hodgkin Lymphoma
PharmaMar as a Foundational Partner of OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition
What’s New On Radiotherapy of Lung Cancer in 2026?
ALICE Trial at IGCS 2026: Reduced Surgical Morbidity in Endometrial Cancer Staging
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
